Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.

Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Oct 15;68(20):8286-94. doi: 10.1158/0008-5472.CAN-07-6316.

2.

LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.

Stutz MA, Shattuck DL, Laederich MB, Carraway KL 3rd, Sweeney C.

Oncogene. 2008 Sep 25;27(43):5741-52. doi: 10.1038/onc.2008.185. Epub 2008 Jun 9.

3.

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Mar 1;68(5):1471-7. doi: 10.1158/0008-5472.CAN-07-5962.

4.

LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.

Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL 3rd, Sweeney C.

Mol Cell Biol. 2007 Mar;27(5):1934-46. Epub 2006 Dec 18.

5.

ErbB receptor negative regulatory mechanisms: implications in cancer.

Sweeney C, Miller JK, Shattuck DL, Carraway KL 3rd.

J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):89-99. Review.

PMID:
16865534
6.

Chemical and biological differentiation of three human breast cancer cell types using time-of-flight secondary ion mass spectrometry.

Kulp KS, Berman ES, Knize MG, Shattuck DL, Nelson EJ, Wu L, Montgomery JL, Felton JS, Wu KJ.

Anal Chem. 2006 Jun 1;78(11):3651-8.

PMID:
16737220
7.

Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells.

Kulp KS, Montgomery JL, Nelson DO, Cutter B, Latham ER, Shattuck DL, Klotz DM, Bennett LM.

Breast Cancer Res Treat. 2006 Aug;98(3):249-59. Epub 2006 Mar 16.

PMID:
16541326

Supplemental Content

Loading ...
Support Center